𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis

✍ Scribed by Soichi Kobayashi; Takashi Kishimoto; Shigeyuki Kamata; Masayuki Otsuka; Masaru Miyazaki; Hiroshi Ishikura

Book ID
108583853
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
316 KB
Volume
98
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase 2 study of the oral mammalian ta
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
✍ Brian M. Slomovitz; Karen H. Lu; Taren Johnston; Robert L. Coleman; Mark Munsell πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 118 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110Ξ± catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in cons

Expression of an activated mammalian tar
Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy
✍ Leri S. Faried; Ahmad Faried; Tatsuya Kanuma; Hiroshi Aoki; Takaaki Sano; Tomoko πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 667 KB

## Abstract Alterations of the Akt/mTOR pathway have been observed in numerous types of cancer, thus this pathway represents an exciting new target for molecular therapeutics. We investigated the expression of activated Akt (p‐Akt) and mTOR (p‐mTOR) in patients with adenocarcinoma of the cervix and